BIO-LES Business Development Fundamentals Course Faculty

  • Recommend
  • Tweet
  • Print
  • Email

The 2014 Business Development Fundamentals Course faculty will be announced soon! Please check back.

2013 Business Development Fundamentals Course Faculty

This page shows the 2013 Business Development Fundamentals course faculty members. We also offer an Advanced Business Development course- click here to view the Advanced Business Development faculty.

Anjan Aralihalli
Senior Director, Business Development, Shiongi Inc.

Anjan or "AJ" Aralihalli has close to 20 years of pharmaceutical industry experience in Canada and the US in a variety of functions (clinical development, finance, sales, marketing and business development). He has worked in both big pharma and biotech and, after eight years at Sanofi-Aventis, recently joined the US office of Shionogi, a Japanese pharmaceutical company.

Steven Barrett

Steven Barrett, Esq
Partner & Co-Chair, Technology Transactions & Licensing Practice Group, WilmerHale

Steve Barrett is a partner in WilmerHale's Corporate and Transactional Department, and co-chair of the Technology Transactions and Licensing Practice Group.

Mr. Barrett advises a variety of life sciences and technology companies regarding the structuring, negotiation and drafting of agreements for a broad range of technology transactions, including technology acquisition, license, strategic alliance and joint venture transactions, and related research, development, supply, marketing, distribution and services agreements. Mr. Barrett regularly represents entrepreneurs, early-stage and established life sciences and technology companies and large commercial enterprises.  Steve received his  JD, cum laude from the University of Michigan Law School,  and MBA, with High Distinction from the University of Michigan School of Business Administration and an SB in Mechanical Engineering from the Massachusetts Institute of Technology.

 

Gary C. Cupit, PharmD
CEO & Director, Somnus Therapeutics, Inc.

Dr. Cupit is CEO and Director at Somnus Therapeutics, Inc. Previously, Dr. Cupit held positions asPresident of Enzo Therapeutics, Inc., President and CEO of Sapphire Therapeutics and Vice President, Global Business Development and Licensing at Novartis. Before Novartis, Dr. Cupit held executive and managerial positions in business development, marketing and sales for Knoll Pharmaceutical,and SmithKline Beecham.. Prior to joining the pharmaceutical industry, Dr. Cupit held faculty positions at New York Hospital-Cornell Medical Center, the University of California, San Francisco, and the University of Pennsylvania and the University of Tennessee, Memphis. Dr. Cupit earned his Bachelor of Science in Pharmacy from the Medical College of Virginia and Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science.

Steven Davis

Steven Davis, Ph.D.
Partner, McCarter & English, LLP

Steven G. Davis is a partner with McCarter & English, LLP. Dr. Davis is a member of the Intellectual Property and Information Technology practice group.

Dr. Davis' practice focuses on patent prosecution, portfolio strategy and management, freedom to operate assessments, infringement analysis, patent issues related to IPOs, and intellectual property licensing. He assists universities, start-ups, and major pharmaceutical corporations with protecting technologies in the areas of chemistry, pharmaceuticals, and biotechnology, with a particular emphasis in organic chemistry. Of particular interest is advising venture capital investors with due diligence investigations and advising other clients prior to acquiring intellectual property assets.

Dr. Davis has practiced patent law for 18 years both in private practice and as in-house patent counsel for Eli Lilly & Co. His clients also benefit from his experience in industry as a research scientist.

Dr. Davis has co-authored eight scientific publications and is a co-inventor on U.S. Patent 5,073,564 covering photo activated insecticides. After completing graduate school, he worked for five years conducting research in the areas of pesticide chemistry and the preparation of compounds containing stable isotopes. Dr. Davis is committed to the promotion of early-stage technologies.

Dr. Davis has been recognized as a Chambers USA "Leaders in their Field" lawyer for 2010 and 2012.

C. Peter Giuliano
Founder & Chairman, ECG

Peter Giuliano is founder and Chairman of ECG, the communication strategy company. Over more than two decades, Peter and ECG President Frank J. Carillo have guided the firm to a leadership position in its field through their use of proprietary teaching methods and their broad-based communication expertise.

For 21 years, Peter has worked with CEOs, managers and professional staffs of companies ranging from large multinationals to recent startups. His clients have included some of the world’s top corporations, among them Unilever, TRW, Computer Sciences Corporation, Corning Incorporated, The World Bank, Roche Pharmaceuticals and The Associated Press. He has also been a consultant and trainer to a number of government agencies, including the US Department of Commerce, The Federal Reserve Board, The FBI, The International Finance Corporation division of the World Bank, the Veterans Administration, and the Federal Quality Institute, and he has counseled and trained executives of major trade and professional associations in the U.S. and Europe.

Peter credits his background in theater, combined with his business and training experience, as a key factor in his ability to develop in his clients a more effective communications and leadership style.

Rekha Hemrajani
Vice President, Head of Licensing & M&A, Onyx Pharmaceuticals

Rekha Hemrajani has had an eighteen year career focused on the health care and biotech industries both on the financial/deal-making side as well as the operational side of companies.

She is currently Vice President, Head of Licensing and M&A at Onyx Pharmaceuticals, Previously, she was Vice President of Business Development at Exelixis and has been involved in raising over $800 million in capital through business development and other non-dilutive transactions. Prior to Exelixis, she spent several years in investment banking (at Credit Suisse First Boston and at Lehman Brothers) helping large, small and mid-sized companies in the biopharmaceutical and healthcare industries raise capital in the public and private markets, as well as with mergers and acquisitions. During her almost six year tenure in investment banking, she was involved in raising over $8 billion in debt and equity capital as well as over $2 billion in M&A transactions.

In addition, Rekha has also worked in emerging markets, and has maintained a strong tie to the medical industry in India. Rekha is a member of the Board of Directors of Hemmo Pharmaceuticals Pvt. Ltd. (manufacturer of synthetic peptides) in Mumbai, India.

Rekha has a Bachelor of Science degree from the University of Michigan in Ann Arbor, and an MBA from the Kellogg School of Management at Northwestern University.

Christopher Lynch

Christopher Lynch
Director of Licensing & Acquisitions, Abbvie

Dr. Lynch is a Director in the Scientific Assessment and Technology Licensing group within the Licensing and Acquisitions organization at AbbVie.  During his 10 years at AbbVie, Christopher has held a variety of roles in R&D and licensing.  Prior to joining AbbVie, Christopher was a Research Fellow at Merck & Company in the Department of Medicinal Chemistry in the field of GPCR receptor modulators.  

Christopher received his B.S. in Biochemistry from the University of Wisconsin, M.B.A. from the Cardinal Stritch University and Ph.D. from the University of Wisconsin.  He held a Postdoctoral position in the Department of Chemistry at the University of Texas.  Chris is a Certified Licensing Professional and member the Licensing Executives Society.  

Clare Ozawa

Clare Ozawa, PhD
Chief Business Officer, Inception Sciences

Clare Ozawa is Chief Business Officer of Inception Sciences, a drug discovery incubator located in San Diego, California.  Her past professional experience includes roles in venture capital, pharmaceutical management, and strategy consulting.  Prior to Inception, Clare was a member of the Versant Ventures investment team and played a key role in formation of multiple startup companies including Quanticel Pharmaceuticals and Inception Sciences.  She joined Versant from Novartis Pharma in Basel, Switzerland, where she reported directly to the CEO, coordinating activities of the Office of the CEO and leading initiatives mandated by the Novartis Pharma Executive Committee.  

Previously, Clare was a senior Engagement Manager at McKinsey & Company, a global management consulting firm, where she advised clients on commercial, operational and strategy issues across the biopharmaceutical sector. Clare earned a Bachelor of Sciences degree in Biological Sciences with honors and distinction from Stanford University, and a Ph.D. in Neurosciences from Stanford University Medical School.

Neel Patel
Practice Executive, Campbell Alliance

Neel Patel brings to Campbell Alliance more than 15 years of experience advising companies primarily focused in life-sciences and healthcare. He has a broad network in the life-sciences private equity community, management consulting, corporate development, and transaction advisory work. Mr. Patel has completed regional and cross-border M&A, licensing, and financing transactions for biotech and large pharma companies, and has over eight years of management consulting experience with clients across several industries to improve their competitive positions through a combination of growth, cost-cutting, and asset effectiveness initiatives.

Before joining Campbell Alliance, Mr. Patel was a member of Burrill & Company’s Merchant Banking Group where he managed strategic transactions for clients through advisory work. Transactions included mergers and acquisitions, partnering/licensing, and financing. Prior to that role, Mr. Patel was a management consultant with AT Kearney and Mercer Management Consulting. His experience includes strategy and operations consulting to international corporate clients in Pharmaceuticals, Biotech, Healthcare, Diagnostics, High Tech, and Consumer Goods.

Jake Schaible
President, Toscana Ventures, Inc.

Toscana Ventures, Inc. is a boutique New Venture / Business Development Consultancy based in San Diego, California. The firm focuses on the incubation of new BioPharma venture concepts, as well as assisting other emerging biopharmaceuticals with their own fundraising and transactional support needs.

John Selig

John Selig, Esq
Managing Director, Woodside Capital Partners

John Selig is a Managing Director and co-head of the Life Sciences Group at Woodside Capital Partners. He advises companies on M&A, licensing and finance strategy.

Prior to joining Woodside, he was a Partner at Keelin Reeds Partners, a life sciences management consulting firm, where he advised dozens of VC-backed and small cap biopharmaceutical, medical device and diagnostics companies on M&A and licensing strategies, portfolio management, valuation and strategic direction. While at KR, John led a partnership deal term benchmarking effort and has extensive experience in applying that data to yield market-value deal terms for dozens of assets, using the results to inform product strategy and to provide ongoing support during deal negotiations. John also combined his expertise in valuation, deal term benchmarking and decision analysis with his background in law to help companies make optimal decisions in litigation and settlement.

Previously, John was a senior consultant with Strategic Decisions Group, a global management consulting firm, where he advised numerous Fortune 500 companies in life sciences and other industries on valuation, business strategy and M&A. Prior to consulting, John was an attorney with Weil, Gotshal & Manges LLP where he focused on M&A and corporate finance.

John holds a JD from Stanford Law School and a BA from Brown University.

Patricia Sinatra

Patricia Sinatra
Managing Director, Vector Strategic Advisors

Since 2006, Patricia has organized and served as faculty for the BIO/LES Business Development Basics Course. She has more than 20 years of licensing and commercial drug development experience and is currently the Managing Director at Vector Strategic Advisors which provides licensing and strategic advisory services for small and sized biopharma companies. Prior to Vector, Pat served as Vice President of Business Development and Corporate Strategy for Telome Health Inc, and VP of Business Development and Commercial Strategy for Sutro Biopharma, Inc.  Previously, Pat was Sr. Director of Business Development and Alliance Management for Dynavax Technologies, and was Director of Business Development at Abgenix, where in addition to her licensing and alliance management responsibilities she managed strategic marketing initiatives for the company’s oncology and inflammation portfolio. She also held positions of increasingly responsibility for Matrix Pharmaceutical, ALZA (formerly SEQUUS®) Pharmaceuticals, FCB Healthcare, SmithKline Beecham plc, and Fujisawa-SmithKline Pharmaceuticals.

Pat conducted post-graduate doctoral level studies in microbiology at the University of Texas Southwestern Graduate School of Biomedical Sciences and has a B.S. degree in biology from the State University of New York.

 

Kenneth Weber, PhD
Kilpatrick Townsend & Stockton LLP

Kenneth Weber, PhD, focuses his practice on patent prosecution, particularly in the areas of molecular genetics, chemistry, pharmaceuticals, plant science, medical devices and microbial genetics. He regularly assists clients in patent portfolio management, due diligence reviews, validity/infringement opinions and licensing.

Dr. Weber's clients include public and private corporations across the United States. Representative corporate clients include Aqua Bounty Technologies; Avanir, Inc.; Biosensors International; and Corcept Therapeutics, Cepheid, Inc., Ciphergen Biosystems, Inc. and Sutro Biopharma based in California. Ken is a member of the American Bar Association and the American Intellectual Property Law Association. He received his J.D. degree from the University of Washington and holds a PhD in Plant Pathology.